Toxin and Immunotoxin Based Therapeutic Approaches
In 1900, Paul Ehrlich, who was studying ricin and abrin at the time, discovered antibodies and paved the way for immunotherapy. After 120 years, Ehrlich’s insight into the therapeutic potential of immunotargeting is still a source of inspiration for many scientists. One of the most studied antibody-...
Gorde:
| Formatua: | Online |
|---|---|
| Hizkuntza: | ingelesa |
| Argitaratua: |
MDPI - Multidisciplinary Digital Publishing Institute
2022
|
| Gaiak: | |
| Sarrera elektronikoa: | ONIX_20220224_9783036530659_132 |
| Etiketak: |
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|
| _version_ | 1869528720095576064 |
|---|---|
| collection | Directory of Open Access Books |
| description | In 1900, Paul Ehrlich, who was studying ricin and abrin at the time, discovered antibodies and paved the way for immunotherapy. After 120 years, Ehrlich’s insight into the therapeutic potential of immunotargeting is still a source of inspiration for many scientists. One of the most studied antibody-based targeting strategies is the carrying of powerful toxins. The generated molecules are immunotoxins, i.e., chimeric proteins obtained by coupling bacterial or plant toxins and antibodies through chemical linking or genetic engineering. Immunotoxins are functionally designed to eliminate the cells responsible for pathological conditions, and they find applications in several fields, ranging from cancer to immunological diseases or pain control. Despite the lack of specificity, even native toxins find clinical application, but the use of unconjugated toxins is limited to loco-regional treatments. A fundamental requirement for the medical application of toxins and their immunoconjugates is in-depth knowledge of their interaction with target cells in terms of binding, uptake, intracellular routing, and substrate specificity. This Special Issue focuses on toxins and immunotoxins that have clinical potential. We hope to give the reader a comprehensive overview of new toxin delivery strategies and toxin-based experimental disease models, both in vitro and in vivo. |
| format | Online |
| id | doab-20.500.12854ir-78835 |
| institution | Directory of Open Access Books |
| language | eng |
| publishDate | 2022 |
| publishDateRange | 2022 |
| publishDateSort | 2022 |
| publisher | MDPI - Multidisciplinary Digital Publishing Institute |
| publisherStr | MDPI - Multidisciplinary Digital Publishing Institute |
| record_format | ojs |
| spelling | doab-20.500.12854ir-788352024-04-01T23:19:27Z Toxin and Immunotoxin Based Therapeutic Approaches Bortolotti, Massimo Polito, Letizia Bolognesi, Andrea 3D structure plant toxin primary sequence ribosome-inactivating protein stenodactylin toxic lectin fusion proteins ricin pokeweed antiviral protein COVID-19 SARS-CoV-2 antiviral agent ribosome-inactivating proteins monoclonal antibody immunotoxin antibody drug conjugate immunoliposome drug delivery diphtheria toxin DT3C prostate cancer targeted toxins epidermal growth factor epidermal growth factor receptor Pseudomonas Exotoxin A patient-derived glioblastoma cell lines Chenopodium quinoa wild quinoin temozolomide Glypican-3 hepatocellular carcinoma humanized YP7 new recombinant immunotoxin kirkiin sugar specificity cancer therapy n/a thema EDItEUR::N History and Archaeology::NH History thema EDItEUR::J Society and Social Sciences::JB Society and culture: general::JBF Social and ethical issues In 1900, Paul Ehrlich, who was studying ricin and abrin at the time, discovered antibodies and paved the way for immunotherapy. After 120 years, Ehrlich’s insight into the therapeutic potential of immunotargeting is still a source of inspiration for many scientists. One of the most studied antibody-based targeting strategies is the carrying of powerful toxins. The generated molecules are immunotoxins, i.e., chimeric proteins obtained by coupling bacterial or plant toxins and antibodies through chemical linking or genetic engineering. Immunotoxins are functionally designed to eliminate the cells responsible for pathological conditions, and they find applications in several fields, ranging from cancer to immunological diseases or pain control. Despite the lack of specificity, even native toxins find clinical application, but the use of unconjugated toxins is limited to loco-regional treatments. A fundamental requirement for the medical application of toxins and their immunoconjugates is in-depth knowledge of their interaction with target cells in terms of binding, uptake, intracellular routing, and substrate specificity. This Special Issue focuses on toxins and immunotoxins that have clinical potential. We hope to give the reader a comprehensive overview of new toxin delivery strategies and toxin-based experimental disease models, both in vitro and in vivo. 2022-02-24T10:38:09Z 2022-02-24T10:38:09Z 2022 book ONIX_20220224_9783036530659_132 9783036530659 9783036530642 https://directory.doabooks.org/handle/20.500.12854/78835 eng image/jpeg Attribution 4.0 International https://mdpi.com/books/pdfview/book/4929 https://mdpi.com/books/pdfview/book/4929 MDPI - Multidisciplinary Digital Publishing Institute 10.3390/books978-3-0365-3065-9 10.3390/books978-3-0365-3065-9 46cabcaa-dd94-4bfe-87b4-55023c1b36d0 9783036530659 9783036530642 122 Basel open access |
| spellingShingle | 3D structure plant toxin primary sequence ribosome-inactivating protein stenodactylin toxic lectin fusion proteins ricin pokeweed antiviral protein COVID-19 SARS-CoV-2 antiviral agent ribosome-inactivating proteins monoclonal antibody immunotoxin antibody drug conjugate immunoliposome drug delivery diphtheria toxin DT3C prostate cancer targeted toxins epidermal growth factor epidermal growth factor receptor Pseudomonas Exotoxin A patient-derived glioblastoma cell lines Chenopodium quinoa wild quinoin temozolomide Glypican-3 hepatocellular carcinoma humanized YP7 new recombinant immunotoxin kirkiin sugar specificity cancer therapy n/a thema EDItEUR::N History and Archaeology::NH History thema EDItEUR::J Society and Social Sciences::JB Society and culture: general::JBF Social and ethical issues Toxin and Immunotoxin Based Therapeutic Approaches |
| title | Toxin and Immunotoxin Based Therapeutic Approaches |
| title_full | Toxin and Immunotoxin Based Therapeutic Approaches |
| title_fullStr | Toxin and Immunotoxin Based Therapeutic Approaches |
| title_full_unstemmed | Toxin and Immunotoxin Based Therapeutic Approaches |
| title_short | Toxin and Immunotoxin Based Therapeutic Approaches |
| title_sort | toxin and immunotoxin based therapeutic approaches |
| topic | 3D structure plant toxin primary sequence ribosome-inactivating protein stenodactylin toxic lectin fusion proteins ricin pokeweed antiviral protein COVID-19 SARS-CoV-2 antiviral agent ribosome-inactivating proteins monoclonal antibody immunotoxin antibody drug conjugate immunoliposome drug delivery diphtheria toxin DT3C prostate cancer targeted toxins epidermal growth factor epidermal growth factor receptor Pseudomonas Exotoxin A patient-derived glioblastoma cell lines Chenopodium quinoa wild quinoin temozolomide Glypican-3 hepatocellular carcinoma humanized YP7 new recombinant immunotoxin kirkiin sugar specificity cancer therapy n/a thema EDItEUR::N History and Archaeology::NH History thema EDItEUR::J Society and Social Sciences::JB Society and culture: general::JBF Social and ethical issues |
| topic_facet | 3D structure plant toxin primary sequence ribosome-inactivating protein stenodactylin toxic lectin fusion proteins ricin pokeweed antiviral protein COVID-19 SARS-CoV-2 antiviral agent ribosome-inactivating proteins monoclonal antibody immunotoxin antibody drug conjugate immunoliposome drug delivery diphtheria toxin DT3C prostate cancer targeted toxins epidermal growth factor epidermal growth factor receptor Pseudomonas Exotoxin A patient-derived glioblastoma cell lines Chenopodium quinoa wild quinoin temozolomide Glypican-3 hepatocellular carcinoma humanized YP7 new recombinant immunotoxin kirkiin sugar specificity cancer therapy n/a thema EDItEUR::N History and Archaeology::NH History thema EDItEUR::J Society and Social Sciences::JB Society and culture: general::JBF Social and ethical issues |
| url | ONIX_20220224_9783036530659_132 |